Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DCTN6

Gene summary for DCTN6

Gene summary.

Gene information	Species	Human
	Gene symbol	DCTN6
	Gene ID	10671
	Gene name	dynactin subunit 6
	Gene Alias	WS-3
	Cytomap	8p12
	Gene Type	protein-coding
	GO ID	GO:0000226
	UniProtAcc	O00399

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
10671	DCTN6	LZE4T	Human	Esophagus	ESCC	1.41e-07	2.32e-01	0.0811
10671	DCTN6	LZE8T	Human	Esophagus	ESCC	1.95e-09	1.60e-01	0.067
10671	DCTN6	LZE20T	Human	Esophagus	ESCC	1.77e-07	6.50e-02	0.0662
10671	DCTN6	LZE24T	Human	Esophagus	ESCC	2.88e-07	2.28e-01	0.0596
10671	DCTN6	LZE21T	Human	Esophagus	ESCC	1.11e-04	2.33e-01	0.0655
10671	DCTN6	LZE6T	Human	Esophagus	ESCC	1.80e-10	1.66e-01	0.0845
10671	DCTN6	P1T-E	Human	Esophagus	ESCC	1.48e-06	3.54e-01	0.0875
10671	DCTN6	P2T-E	Human	Esophagus	ESCC	2.53e-28	5.61e-01	0.1177
10671	DCTN6	P4T-E	Human	Esophagus	ESCC	5.59e-28	8.21e-01	0.1323
10671	DCTN6	P5T-E	Human	Esophagus	ESCC	1.95e-19	2.76e-01	0.1327
10671	DCTN6	P8T-E	Human	Esophagus	ESCC	2.88e-22	4.43e-01	0.0889
10671	DCTN6	P9T-E	Human	Esophagus	ESCC	1.58e-13	4.05e-01	0.1131
10671	DCTN6	P10T-E	Human	Esophagus	ESCC	6.31e-38	5.28e-01	0.116
10671	DCTN6	P11T-E	Human	Esophagus	ESCC	1.52e-19	8.09e-01	0.1426
10671	DCTN6	P12T-E	Human	Esophagus	ESCC	3.67e-18	3.17e-01	0.1122
10671	DCTN6	P15T-E	Human	Esophagus	ESCC	3.66e-41	1.05e+00	0.1149
10671	DCTN6	P16T-E	Human	Esophagus	ESCC	1.63e-34	5.28e-01	0.1153
10671	DCTN6	P17T-E	Human	Esophagus	ESCC	5.21e-15	3.56e-01	0.1278
10671	DCTN6	P19T-E	Human	Esophagus	ESCC	9.15e-05	6.40e-01	0.1662
10671	DCTN6	P20T-E	Human	Esophagus	ESCC	3.44e-24	5.02e-01	0.1124

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:190285015	Esophagus	ESCC	microtubule cytoskeleton organization involved in mitosis	116/8552	147/18723	1.25e-16	9.91e-15	116
GO:000705214	Esophagus	ESCC	mitotic spindle organization	97/8552	120/18723	2.17e-15	1.33e-13	97
GO:000705114	Esophagus	ESCC	spindle organization	134/8552	184/18723	5.70e-14	2.87e-12	134
GO:00070526	Oral cavity	OSCC	mitotic spindle organization	85/7305	120/18723	1.44e-12	6.23e-11	85
GO:19028506	Oral cavity	OSCC	microtubule cytoskeleton organization involved in mitosis	99/7305	147/18723	2.94e-12	1.18e-10	99
GO:00070517	Oral cavity	OSCC	spindle organization	117/7305	184/18723	1.16e-11	4.17e-10	117
GO:190285014	Oral cavity	LP	microtubule cytoskeleton organization involved in mitosis	63/4623	147/18723	9.97e-07	2.50e-05	63
GO:000705213	Oral cavity	LP	mitotic spindle organization	53/4623	120/18723	2.36e-06	5.22e-05	53
GO:000705113	Oral cavity	LP	spindle organization	72/4623	184/18723	9.67e-06	1.78e-04	72
GO:190285016	Skin	cSCC	microtubule cytoskeleton organization involved in mitosis	85/4864	147/18723	2.66e-16	2.39e-14	85
GO:000705215	Skin	cSCC	mitotic spindle organization	73/4864	120/18723	7.81e-16	6.80e-14	73
GO:000705115	Skin	cSCC	spindle organization	96/4864	184/18723	2.59e-14	1.77e-12	96
GO:000705116	Thyroid	PTC	spindle organization	92/5968	184/18723	2.21e-07	3.92e-06	92
GO:19028509	Thyroid	PTC	microtubule cytoskeleton organization involved in mitosis	76/5968	147/18723	4.49e-07	7.38e-06	76
GO:000705216	Thyroid	PTC	mitotic spindle organization	64/5968	120/18723	8.69e-07	1.32e-05	64
GO:190285017	Thyroid	ATC	microtubule cytoskeleton organization involved in mitosis	95/6293	147/18723	1.29e-14	7.62e-13	95
GO:000705222	Thyroid	ATC	mitotic spindle organization	80/6293	120/18723	1.27e-13	6.46e-12	80
GO:000705122	Thyroid	ATC	spindle organization	109/6293	184/18723	7.99e-13	3.46e-11	109

Page: 1

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05014210	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa05132211	Esophagus	ESCC	Salmonella infection	191/4205	249/8465	6.51e-19	5.45e-17	2.79e-17	191
hsa05016210	Esophagus	ESCC	Huntington disease	226/4205	306/8465	1.38e-18	8.72e-17	4.46e-17	226
hsa05022210	Esophagus	ESCC	Pathways of neurodegeneration - multiple diseases	318/4205	476/8465	6.10e-15	2.04e-13	1.05e-13	318
hsa0496223	Esophagus	ESCC	Vasopressin-regulated water reabsorption	33/4205	44/8465	5.27e-04	1.78e-03	9.13e-04	33
hsa0501438	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa05132310	Esophagus	ESCC	Salmonella infection	191/4205	249/8465	6.51e-19	5.45e-17	2.79e-17	191
hsa0501638	Esophagus	ESCC	Huntington disease	226/4205	306/8465	1.38e-18	8.72e-17	4.46e-17	226
hsa0502238	Esophagus	ESCC	Pathways of neurodegeneration - multiple diseases	318/4205	476/8465	6.10e-15	2.04e-13	1.05e-13	318
hsa0496233	Esophagus	ESCC	Vasopressin-regulated water reabsorption	33/4205	44/8465	5.27e-04	1.78e-03	9.13e-04	33
hsa0501428	Oral cavity	OSCC	Amyotrophic lateral sclerosis	246/3704	364/8465	6.65e-21	1.11e-18	5.67e-19	246
hsa0513230	Oral cavity	OSCC	Salmonella infection	174/3704	249/8465	2.67e-17	1.49e-15	7.58e-16	174
hsa0501628	Oral cavity	OSCC	Huntington disease	204/3704	306/8465	1.70e-16	7.13e-15	3.63e-15	204
hsa0502228	Oral cavity	OSCC	Pathways of neurodegeneration - multiple diseases	292/3704	476/8465	1.60e-15	4.47e-14	2.28e-14	292
hsa049626	Oral cavity	OSCC	Vasopressin-regulated water reabsorption	29/3704	44/8465	2.47e-03	6.52e-03	3.32e-03	29
hsa05014112	Oral cavity	OSCC	Amyotrophic lateral sclerosis	246/3704	364/8465	6.65e-21	1.11e-18	5.67e-19	246
hsa05132114	Oral cavity	OSCC	Salmonella infection	174/3704	249/8465	2.67e-17	1.49e-15	7.58e-16	174
hsa05016112	Oral cavity	OSCC	Huntington disease	204/3704	306/8465	1.70e-16	7.13e-15	3.63e-15	204
hsa05022112	Oral cavity	OSCC	Pathways of neurodegeneration - multiple diseases	292/3704	476/8465	1.60e-15	4.47e-14	2.28e-14	292
hsa0496213	Oral cavity	OSCC	Vasopressin-regulated water reabsorption	29/3704	44/8465	2.47e-03	6.52e-03	3.32e-03	29

Page: 1 2

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DCTN6

SNV

Missense_Mutation

novel

c.122N>C

p.Ile41Thr

p.I41T

O00399

protein_coding

deleterious(0)

probably_damaging(0.956)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DCTN6

SNV

Missense_Mutation

rs372379363

c.374T>C

p.Ile125Thr

p.I125T

O00399

protein_coding

deleterious(0.04)

possibly_damaging(0.886)

TCGA-HN-A2NL-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

DCTN6

SNV

Missense_Mutation

c.398N>T

p.Thr133Ile

p.T133I

O00399

protein_coding

deleterious(0.04)

benign(0.424)

TCGA-FU-A3HZ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

DCTN6

SNV

Missense_Mutation

rs758874465

c.403N>A

p.Glu135Lys

p.E135K

O00399

protein_coding

deleterious(0.03)

probably_damaging(0.992)

TCGA-VS-A9UJ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

DCTN6

SNV

Missense_Mutation

novel

c.76N>T

p.Asp26Tyr

p.D26Y

O00399

protein_coding

deleterious(0)

probably_damaging(0.975)

TCGA-AG-A002-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

DCTN6

SNV

Missense_Mutation

novel

c.292N>A

p.Ala98Thr

p.A98T

O00399

protein_coding

deleterious(0.05)

benign(0.305)

TCGA-A5-A0G1-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

DCTN6

SNV

Missense_Mutation

novel

c.298A>G

p.Lys100Glu

p.K100E

O00399

protein_coding

tolerated(0.22)

benign(0.091)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

DCTN6

SNV

Missense_Mutation

novel

c.226G>T

p.Asp76Tyr

p.D76Y

O00399

protein_coding

deleterious(0.04)

benign(0.235)

TCGA-AP-A1DV-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

DCTN6

SNV

Missense_Mutation

novel

c.59N>G

p.Glu20Gly

p.E20G

O00399

protein_coding

deleterious(0)

probably_damaging(0.951)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

DCTN6

SNV

Missense_Mutation

novel

c.317N>C

p.Val106Ala

p.V106A

O00399

protein_coding

deleterious(0.04)

probably_damaging(0.913)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1